DE69635516T2 - Verwendung von Emulsionen enthaltend in lipide eingeschlossene flussige Fluorocarbone für gezielte diagnostische Verfahren in vivo - Google Patents

Verwendung von Emulsionen enthaltend in lipide eingeschlossene flussige Fluorocarbone für gezielte diagnostische Verfahren in vivo Download PDF

Info

Publication number
DE69635516T2
DE69635516T2 DE69635516T DE69635516T DE69635516T2 DE 69635516 T2 DE69635516 T2 DE 69635516T2 DE 69635516 T DE69635516 T DE 69635516T DE 69635516 T DE69635516 T DE 69635516T DE 69635516 T2 DE69635516 T2 DE 69635516T2
Authority
DE
Germany
Prior art keywords
emulsion
biotinylated
avidin
acoustic
pbs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69635516T
Other languages
German (de)
English (en)
Other versions
DE69635516D1 (de
Inventor
M. Gregory LANZA
A. Samuel WICKLINE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Barnes Hospital
Original Assignee
Barnes Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/488,743 external-priority patent/US5690907A/en
Application filed by Barnes Hospital filed Critical Barnes Hospital
Publication of DE69635516D1 publication Critical patent/DE69635516D1/de
Application granted granted Critical
Publication of DE69635516T2 publication Critical patent/DE69635516T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/586—Liposomes, microcapsules or cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Hydrogenated Pyridines (AREA)
DE69635516T 1995-06-08 1996-06-06 Verwendung von Emulsionen enthaltend in lipide eingeschlossene flussige Fluorocarbone für gezielte diagnostische Verfahren in vivo Expired - Fee Related DE69635516T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/488,743 US5690907A (en) 1995-06-08 1995-06-08 Avidin-biotin conjugated emulsions as a site specific binding system
US488743 1995-06-08
US08/647,277 US5780010A (en) 1995-06-08 1996-05-23 Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
US647277 1996-05-23
PCT/US1996/010425 WO1996041647A1 (en) 1995-06-08 1996-06-06 Site specific binding system, imaging compositions and methods

Publications (2)

Publication Number Publication Date
DE69635516D1 DE69635516D1 (de) 2006-01-05
DE69635516T2 true DE69635516T2 (de) 2006-08-10

Family

ID=27049460

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69635516T Expired - Fee Related DE69635516T2 (de) 1995-06-08 1996-06-06 Verwendung von Emulsionen enthaltend in lipide eingeschlossene flussige Fluorocarbone für gezielte diagnostische Verfahren in vivo

Country Status (8)

Country Link
US (2) US5780010A (https=)
EP (1) EP0831933B1 (https=)
JP (1) JP4082463B2 (https=)
AU (1) AU710837B2 (https=)
CA (1) CA2222544C (https=)
DE (1) DE69635516T2 (https=)
ES (1) ES2252755T3 (https=)
WO (1) WO1996041647A1 (https=)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150539A1 (en) 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US5958371A (en) * 1995-06-08 1999-09-28 Barnes-Jewish Hospital Site specific binding system, nuclear imaging compositions and methods
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US20070036722A1 (en) * 1996-10-28 2007-02-15 Pal Rongved Separation processes
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
ES2257771T3 (es) 1996-10-28 2006-08-01 Amersham Health As Agentes de contraste.
EP0991427A2 (en) * 1996-10-28 2000-04-12 Marsden, John Christopher Improvements in or relating to diagnostic/therapeutic agents
CA2270120A1 (en) 1996-10-28 1998-05-07 Pal Rongved Improvements in or relating to diagnostic/therapeutic agents
EP0973552B1 (en) * 1996-10-28 2006-03-01 Amersham Health AS Improvements in or relating to diagnostic/therapeutic agents
BR9713978A (pt) * 1996-10-28 2000-05-02 Nycomed Imaging As Agente diagnóstico alvejável e/ou terapeuticamente ativo, processo para preparação e uso do mesmo, formulação combinada, e, processos para gerar imagens intensificadas de um corpo animal humano ou não-humano e para investigação in vitro de alvejamento por um agente
EP0963209A2 (en) * 1996-10-28 1999-12-15 Marsden, John Christopher Improvements in or relating to diagnostic/therapeutic agents
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
AU7104598A (en) * 1997-04-09 1998-10-30 Philipp Lang New technique to monitor drug delivery noninvasively (in vivo)
US7452551B1 (en) 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) * 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
JP2003521475A (ja) * 1999-05-25 2003-07-15 バーンズ−ジューウィッシュ・ホスピタル 部位特異的結合系、核画像化組成物及び方法
AU762944B2 (en) * 1999-06-23 2003-07-10 Cornell Research Foundation Inc. Dehydration/rehydration of marked liposomes on a test device
WO2001005433A2 (en) * 1999-07-14 2001-01-25 Board Of Regents, The University Of Texas System Delivery and retention of activity agents to lymph nodes
US7220401B2 (en) * 1999-09-24 2007-05-22 Barnes-Jewish Hospital Blood clot-targeted nanoparticles
US6576460B1 (en) 1999-10-28 2003-06-10 Cornell Research Foundation, Inc. Filtration-detection device and method of use
US20020103165A1 (en) * 2000-02-29 2002-08-01 Alliance Pharmaceutical Corp., Engineered spray-dried lipid-based microparticles for cellular targeting
US6676963B1 (en) * 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US7179449B2 (en) * 2001-01-30 2007-02-20 Barnes-Jewish Hospital Enhanced ultrasound detection with temperature-dependent contrast agents
US7279150B2 (en) * 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
KR100978126B1 (ko) 2002-01-24 2010-08-26 반즈 쥬이쉬 하스피털 인테그린 표적화 조영제
CA2478822C (en) 2002-03-11 2016-07-12 Passport Technologies, Inc. Transdermal drug delivery patch system, method of making same and method of using same
US6869591B2 (en) * 2002-03-26 2005-03-22 Barnes-Jewish Hospital Paramagnetic particles that provide improved relaxivity
DE60318435T2 (de) 2002-05-31 2008-12-24 Cornell Research Foundation, Inc. Universeller biosensor und verfahren zur verwendung
JP2007521254A (ja) * 2003-06-25 2007-08-02 ゲルベ 診断画像用化合物
WO2005014051A1 (en) * 2003-08-08 2005-02-17 Barnes-Jewish Hospital Emulsion particles for imaging and therapy and methods of use thereof
JP2007511616A (ja) * 2003-11-19 2007-05-10 バーンズ−ジューイッシュ ホスピタル 増強された薬物送達
WO2005077407A1 (en) * 2004-01-16 2005-08-25 Barnes-Jewish Hospital Targeted atherosclerosis treatment
EP1713513B1 (en) 2004-01-16 2014-06-04 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
EP1768558A4 (en) 2004-06-09 2009-11-25 Kereos Inc LIPOPHILES DERIVATIVES OF CHELATE MONOAMIDES
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2006096499A2 (en) * 2005-03-04 2006-09-14 Washington University Mr coronary angiography with a fluorinated nanoparticle contrast agent at 1.5 t
EP1716870A1 (en) * 2005-04-29 2006-11-02 Bracco Imaging S.p.A. MRI contrast agents endowed with concentration independent responsiveness
US20070048383A1 (en) * 2005-08-25 2007-03-01 Helmus Michael N Self-assembled endovascular structures
US20070232909A1 (en) * 2006-03-28 2007-10-04 Washington University Ultrasonic Characterization of Internal Body Conditions Using Information Theoretic Signal Receivers
EP2010646A2 (en) 2006-04-14 2009-01-07 Carnegie Mellon University Cellular labeling and quantification for nuclear magnetic resonance techniques
US9308198B2 (en) 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
ES2399147T3 (es) 2006-09-08 2013-03-26 Rhode Island Hospital Tratamiento, prevención y reversión de una enfermedad hepática alcohólica
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
JP2008162981A (ja) * 2006-12-28 2008-07-17 Japan Science & Technology Agency ビオチン化ないしホーミングペプチド提示型バイオナノカプセル
US7646198B2 (en) * 2007-03-09 2010-01-12 Case Western Reserve University Methods for fat signal suppression in magnetic resonance imaging
FR2914303A1 (fr) 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
FR2914304B1 (fr) 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
JP5645658B2 (ja) 2007-07-10 2014-12-24 カーネギー メロン ユニバーシティー 核磁気共鳴技術のための細胞標識を製造するための組成物及び方法
EP2209420A4 (en) 2007-10-09 2014-01-22 Univ St Louis PARTICULARS FOR IMAGING
US9468607B2 (en) 2007-10-09 2016-10-18 Washington University Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
EP2112366B1 (en) 2008-04-23 2011-11-02 Magneti Marelli S.p.A. Electromagnetic fuel injector for gaseous fuels with anti-wear stop device
WO2009155335A2 (en) * 2008-06-19 2009-12-23 University Of Maryland, Baltimore Conjugates of 19f mr imaging tracers and chemotherapeutic agents for drug quantification and drug dose individualization
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
JP2013514999A (ja) 2009-12-17 2013-05-02 ワシントン・ユニバーシティ 抗血栓性ナノ粒子
AU2011239414A1 (en) 2010-04-15 2012-11-08 The Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
WO2012159107A1 (en) 2011-05-19 2012-11-22 Rhode Island Hospital Inhibition of renal fibrosis
WO2013116691A1 (en) 2012-02-02 2013-08-08 The Washington University Methods for improving muscle strength
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
WO2015099094A1 (ja) 2013-12-27 2015-07-02 国立大学法人東京医科歯科大学 アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法
US10213448B2 (en) 2016-03-25 2019-02-26 Novazoi Theranostics Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof
US10987315B1 (en) 2018-12-04 2021-04-27 University Of South Florida Antithrombotic nanoparticles and methods for treating necrotizing enterocolitis
JP7196581B2 (ja) * 2018-12-10 2022-12-27 大同特殊鋼株式会社 被検査材の組織検査方法
WO2024208433A1 (en) 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Nanoemulsion without propylene glycol
WO2024208434A1 (en) 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Pressurized nanoemulsion

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US5336762A (en) * 1985-11-18 1994-08-09 Access Pharmaceuticals, Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5171737A (en) * 1989-03-03 1992-12-15 The Liposome Company, Inc. Emulsions
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5242681A (en) * 1990-03-12 1993-09-07 Research Corporation Technologies, Inc. Lipophilic contrast agents for diagnostic image analysis
JP2888936B2 (ja) * 1990-06-28 1999-05-10 株式会社東芝 流体圧縮機
DE4232755A1 (de) * 1992-09-26 1994-03-31 Schering Ag Mikropartikelpräparationen aus biologisch abbaubaren Mischpolymeren
US5571498A (en) * 1994-06-02 1996-11-05 Hemagen/Pfc Emulsions of paramagnetic contrast agents for magnetic resonance imaging (MRI).
US5512294A (en) * 1994-08-05 1996-04-30 Li; King C. Targeted polymerized liposome contrast agents
CA2218541A1 (en) * 1995-06-07 1996-12-19 Imarx Pharmaceutical Corp. Novel targeted compositions for diagnostic and therapeutic use

Also Published As

Publication number Publication date
EP0831933A1 (en) 1998-04-01
AU6179196A (en) 1997-01-09
WO1996041647A1 (en) 1996-12-27
ES2252755T3 (es) 2006-05-16
EP0831933B1 (en) 2005-11-30
JP4082463B2 (ja) 2008-04-30
US5780010A (en) 1998-07-14
JP2001527509A (ja) 2001-12-25
US5989520A (en) 1999-11-23
EP0831933A4 (en) 2001-05-30
CA2222544C (en) 2008-07-22
DE69635516D1 (de) 2006-01-05
CA2222544A1 (en) 1996-12-27
AU710837B2 (en) 1999-09-30

Similar Documents

Publication Publication Date Title
DE69635516T2 (de) Verwendung von Emulsionen enthaltend in lipide eingeschlossene flussige Fluorocarbone für gezielte diagnostische Verfahren in vivo
US5690907A (en) Avidin-biotin conjugated emulsions as a site specific binding system
US5958371A (en) Site specific binding system, nuclear imaging compositions and methods
US5858399A (en) Acoustically reflective liposomes and methods to make and use the same
Lanza et al. In vitro characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy
US4598051A (en) Liposome conjugates and diagnostic methods therewith
KR920010391B1 (ko) 핵자기 공명 조영제의 제조 방법
Tiefenauer et al. Antibody-magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging
US6821506B2 (en) Site specific binding system, imaging compositions and methods
US20100209352A1 (en) Synthesis and conjugation of iron oxide nanoparticles to antibodies for targeting specific cells using fluorescence and mr imaging techniques
Alkan-Onyuksel et al. Development of inherently echogenic liposomes as an ultrasonic contrast agent
US7220401B2 (en) Blood clot-targeted nanoparticles
US6132764A (en) Targeted polymerized liposome diagnostic and treatment agents
DE69716069T2 (de) Verfahren zur elektronspinresonanz-verstärkten magnetresonanzabbildung (esremri) mit dynamischer ex vivo kernpolarisation einer magnetresonanzabbildungssubstanz
US6548046B1 (en) Site specific binding system, imaging compositions and methods
EP2848262A1 (de) Zellspezifisches Targeting durch Nanostrukturierte Trägersysteme
US4859450A (en) Method of NMR imaging using antibody to cardiac myosin
CN117982690A (zh) 一种超声造影剂及其制备方法和应用
Hamilton et al. A physiologic flow chamber model to define intravascular ultrasound enhancement of fibrin using echogenic liposomes
WO2005097208A2 (en) Tissue oxygenation measurements
AU771565B2 (en) Site specific binding system, nuclear imaging compositions and methods
AU2004202725B2 (en) Site specific binding system, nuclear imaging compositions and methods
Zhang et al. Early evaluation of survival of the transplanted ovaries through ultrasound molecular imaging via targeted nanobubbles
EP0948361B1 (en) Magnetic resonance blood pool agents
Lanza et al. Development of a novel site-targeted ultrasonic contrast agent

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Ref document number: 831933

Country of ref document: EP

R082 Change of representative

Ref document number: 831933

Country of ref document: EP